Company intelligence / Profile preview

Newronika

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

AlphaDBS has received CE Mark approval in Europe as an adaptive closed-loop deep brain stimulation implant for Parkinson’s disease. The system continuously adjusts therapy based on real-time neural signals to optimize symptom control and reduce side effects. U.S. clinical trials are planned following FDA IDE approval. Early results support improved personalization over conventional DBS.

Therapeutic areas: Neurology
Modalities: DeviceNeuromodulation device (Deep Brain Stimulation system)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

AlphaDBS

Commercial

Indications: Parkinson's disease

Partnerships

Michael J. Fox Foundation research grant recipient

Beyond the preview

Go deeper on Newronika.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Newronika.

Explore the full profile